BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Ovarian cancer AND RBM10, GPATC9, 8241, ENSG00000182872, CTD-2522E6_5, GPATCH9, KIAA0122, P98175, MGC1132, DXS8237E, ZRANB5, MGC997 AND Prognosis
2963 results:

  • 1. Germline biallelic BRCA2 pathogenic variants and medulloblastoma: an international cohort study.
    Kastellan S; Kalb R; Sajjad B; McReynolds LJ; Giri N; Samuel D; Milde T; Elbracht M; Holzhauer S; Niewisch MR; Kratz CP
    J Hematol Oncol; 2024 Apr; 17(1):26. PubMed ID: 38685107
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Cardiovascular mortality risk in patients with ovarian cancer: a population-based study.
    Hu ZL; Yuan YX; Xia MY; Li Y; Yang Y; Wang SN; Meng XZ; Sun MY; Wang N
    J Ovarian Res; 2024 Apr; 17(1):88. PubMed ID: 38664732
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. A novel TCGA-validated programmed cell-death-related signature of ovarian cancer.
    Cai X; Lin J; Liu L; Zheng J; Liu Q; Ji L; Sun Y
    BMC Cancer; 2024 Apr; 24(1):515. PubMed ID: 38654239
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Machine learning developed a fibroblast-related signature for predicting clinical outcome and drug sensitivity in ovarian cancer.
    Fu W; Feng Q; Tao R
    Medicine (Baltimore); 2024 Apr; 103(16):e37783. PubMed ID: 38640321
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Development and validation of an ultrasound-based deep learning radiomics nomogram for predicting the malignant risk of ovarian tumours.
    Du Y; Xiao Y; Guo W; Yao J; Lan T; Li S; Wen H; Zhu W; He G; Zheng H; Chen H
    Biomed Eng Online; 2024 Apr; 23(1):41. PubMed ID: 38594729
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Characteristics of patients with late recurrence endometrial cancer.
    Çakır İ; Gülseren V; Özdemir İA; Abacı H; Talu ECK; Çakır ZE; Ata C; Kuru O; Gökçü M; Sancı M; Güngördük K
    J Cancer Res Ther; 2024 Jan; 20(1):232-237. PubMed ID: 38554326
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. [Clinical analysis of 12 cases of ovarian yolk sac tumor].
    Liu J; Chu HJ; Shan YP; Song WJ; Chen AP
    Zhonghua Fu Chan Ke Za Zhi; 2024 Mar; 59(3):210-214. PubMed ID: 38544450
    [No Abstract]    [Full Text] [Related]  

  • 8. Frizzled class receptor 5 contributes to ovarian cancer chemoresistance through aldehyde dehydrogenase 1A1.
    Xia Y; Wang S; Sun Y; Wang W; Chang S; Zhang Z; Zhao C
    Cell Commun Signal; 2024 Mar; 22(1):194. PubMed ID: 38539211
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. PURE vs. mixed clear cell ovarian carcinomas: Is there any impact on survival?
    Güzel D; Terek C; Besler A; Serin G; Önal Z; Akman L; Göker E; Ali Şanli U; Zekioğlu O; Özdemir N; Özsaran A; Yildirim N
    Eur J Obstet Gynecol Reprod Biol; 2024 May; 296():321-326. PubMed ID: 38518487
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Association of tet methylcytosine dioxygenase 2 and 5-hydroxymethylcytosine in endometrioid adenocarcinoma and its clinical significance.
    Kuang L; Zhang J; Li Y; Wang Q; Liu J; Zhang B
    BMC Womens Health; 2024 Mar; 24(1):188. PubMed ID: 38515066
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. TMEM120B strengthens breast cancer cell stemness and accelerates chemotherapy resistance via β1-integrin/FAK-TAZ-mTOR signaling axis by binding to MYH9.
    Hu R; Cao Y; Wang Y; Zhao T; Yang K; Fan M; Guan M; Hou Y; Ying J; Ma X; Deng N; Sun X; Zhang Y; Zhang X
    Breast Cancer Res; 2024 Mar; 26(1):48. PubMed ID: 38504374
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. 5 signature genes revealed by single-cell profiling identified unique immune subtypes affecting the prognosis of ovarian cancer.
    Xiang SY; Li QK; Yang Z; Yi Q
    Eur Rev Med Pharmacol Sci; 2024 Mar; 28(5):2051-2062. PubMed ID: 38497886
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Prognostic evaluation of lymph-vascular space invasion in patients with endometrioid and non-endometrioid endometrial cancer: A multicenter study.
    Feng J; Zhang Y; Huang C; Li L; Liu J; Wang J; Guo H; Yao S; Cui Z; Chen G; Gao Q; Sun C; Ma D; Wang B; Li Y; Chu R; Kong B
    Eur J Surg Oncol; 2024 Apr; 50(4):108261. PubMed ID: 38484494
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Screening by Q Exactive liquid chromatography/tandem mass spectrometry identified Choline, 25-hydroxyvitamin D2, and SM(d18:0/16:1(9Z) (OH)) as biomarkers for high-grade serous ovarian cancer.
    Li J; Liu D; Cui M; Wei Z
    J Proteomics; 2024 May; 299():105154. PubMed ID: 38471622
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. RNA m
    Liu X; Wei Q; Yang C; Zhao H; Xu J; Mobet Y; Luo Q; Yang D; Zuo X; Chen N; Yang Y; Li L; Wang W; Yu J; Xu J; Liu T; Yi P
    Exp Mol Med; 2024 Mar; 56(3):600-615. PubMed ID: 38424195
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Review on Sertoli-Leydig Cell Tumours of the Ovary.
    Muscat C; Calleja-Agius J
    Discov Med; 2024 Feb; 36(181):234-247. PubMed ID: 38409829
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Comprehensive machine learning-based preoperative blood features predict the prognosis for ovarian cancer.
    Wu M; Gu S; Yang J; Zhao Y; Sheng J; Cheng S; Xu S; Wu Y; Ma M; Luo X; Zhang H; Wang Y; Zhao A
    BMC Cancer; 2024 Feb; 24(1):267. PubMed ID: 38408960
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. An exosome-derived lncRNA signature identified by machine learning associated with prognosis and biomarkers for immunotherapy in ovarian cancer.
    Cui Y; Zhang W; Lu W; Feng Y; Wu X; Zhuo Z; Zhang D; Zhang Y
    Front Immunol; 2024; 15():1228235. PubMed ID: 38404588
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. A novel CSN5/CRT O-GlcNAc/ER stress regulatory axis in platinum resistance of epithelial ovarian cancer.
    Yan T; Ma X; Zhou K; Cao J; Tian Y; Zheng H; Tong Y; Xie S; Wang Y; Guo L; Lu R
    Int J Biol Sci; 2024; 20(4):1279-1296. PubMed ID: 38385070
    [No Abstract]    [Full Text] [Related]  

  • 20. The significance of lower uterine segment involvement in endometrial cancer.
    Davidesko S; Meirovitz M; Shaco-Levy R; Yarza S; Samueli B; Kezerle Y; Kessous R
    Eur J Surg Oncol; 2024 Mar; 50(3):108007. PubMed ID: 38382274
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 149.